...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A regional cooperative clinical study of radiotherapy for cervical cancer in east and south-east Asian countries.
【24h】

A regional cooperative clinical study of radiotherapy for cervical cancer in east and south-east Asian countries.

机译:东亚和东南亚国家宫颈癌放疗的区域合作临床研究。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: Radiotherapy differed widely in east and south-east Asia because of technical, cultural, and socio-economic differences. With the purpose of standardizing radiotherapy for cervical cancer in the region, an international clinical study was conducted. MATERIALS AND METHODS: Eleven institutions in eight Asian countries participated in the study. Between 1996 and 1998, 210 patients with stage IIIB cervical cancer were enrolled. Patients were treated with a combination of external beam radiotherapy (total dose, 50Gy) and either high-dose-rate (HDR) or low-dose-rate (LDR) intracavitary brachytherapy (ICBT) according to the institutional practice. The planned point A dose was 20-28Gy/4 fractions for HDR-ICBT and 30-40Gy/1-2 fractions for LDR-ICBT. RESULTS: Hundred patients were treated with HDR-ICBT and 110 were treated with LDR-ICBT. The ICBT doses actually delivered to point A ranged widely: 12-32Gy in the HDR group and 26-52.7Gy in the LDR group. The 5-year follow-up rate among the countries differed greatly, from 29% to 100%. The 5-year major complication rates were 6% in the HDR group and 10% in the LDR group. The 5-year overall survival rates were 51.1% in the HDR group and 57.5% in the LDR group. CONCLUSIONS: Although there were several problems with treatment compliance and patients' follow-up, the study suggests that the protocols provided favorable outcomes with acceptable rates of late complications in the treatment of advanced cervical cancer in east and south-east Asia.
机译:目的:由于技术,文化和社会经济方面的差异,东亚和东南亚的放射疗法差异很大。为了使该地区的宫颈癌放疗标准化,开展了一项国际临床研究。材料与方法:八个亚洲国家的11个机构参加了这项研究。在1996年至1998年之间,共招募了210例IIIB期宫颈癌患者。根据机构惯例,对患者进行了外部束放射疗法(总剂量50Gy)和高剂量率(HDR)或低剂量率(LDR)腔内近距离放射治疗(ICBT)的联合治疗。对于HDR-ICBT,计划的A点剂量是20-28Gy / 4份,对于LDR-ICBT,计划的A点剂量是30-40Gy / 1-2份。结果:数百例患者接受了HDR-ICBT治疗,110例接受了LDR-ICBT治疗。实际传递到A点的ICBT剂量范围很广:HDR组为12-32Gy,LDR组为26-52.7Gy。各国的5年随访率差异很大,从29%到100%。 HDR组的5年主要并发症发生率为6%,LDR组为10%。 HDR组的5年总生存率为51.1%,LDR组为57.5%。结论:尽管在治疗依从性和患者随访方面存在若干问题,但该研究表明,该方案在东亚和东南亚晚期宫颈癌的治疗中以良好的晚期并发症发生率提供了令人满意的结果。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号